clinical practice
we’ve got a lot to learn about it in terms of
when is the best time to give it.
What a lot of us have been looking at
is repurposing medications used and
developed for other indications and other
conditions. The one that has had the most
attention is an antimalarial drug called
chloroquine, or a modification of it called
hydroxychloroquine.
Donald Trump, Clive Palmer and a variety
of others have really advocated for its use
and because of that there’s been a lot of
political opinion, and there’s been a lot of
poor science as well. There’s been what we
call observational studies in which we’ve
looked at the outcome of people without
any selection as to who got what therapy.
If you were looking at patients, a doctor
may not give any therapy at all to someone
who looks really well. They might give
therapy to someone who looks really sick,
and it wouldn’t be surprising, therefore,
if the person who was already really sick
would be the one who would have the
higher death rate and you could easily
assume, “Oh, that was because they got
that particular medication,” whereas in fact,
it might be their underlying illnesses.
We always search for randomised
trials, where we don’t have any bias at the
beginning. We determine by the toss of
the coin which patient gets which therapy.
That’s the most rigorous way to work out if a
drug like hydroxychloroquine actually works.
The other thing is that these trials have to be
big. They have to have typically well over a
thousand patients. Otherwise, you may risk
not really being able to show the benefits or
otherwise of a particular therapy.
I know that you are running trials in a
few Queensland hospitals. Do you have
enough sick patients in Queensland?
The trial that we’re undergoing is called
ASCOT – Australasian COVID-19 Trial. The
trial randomises people into four different
arms or four different choices. One is a
person who doesn’t get any antiviral drug.
The second is they get the malaria drug,
hydroxychloroquine. The third is that
they get the HIV drug called lopinavir and
ritonavir. The fourth possibility is they get
the hydroxychloroquine and the HIV drug.
We’ve had 70 hospitals in Australia and
another 11 in New Zealand agree to take
part in this study.
Now there is a thing called Lasagna’s
Law. Lasagna was a very famous clinical
trials expert in the 60s and 70s and he
came up with this law that as soon as you
design the most perfect randomised trial,
suddenly the patients with the condition
that you want to treat and to put into
this trial disappear, and of course, they
come back again when the trial is over.
Unfortunately, in Australia and New
Zealand, because we’ve had such great
efforts in social distancing and control of
the spread of the infection, we’ve got no
patients to enrol in the study.
So we are having to look internationally,
whether that’s in Southeast Asia, or
whether we collaborate with colleagues
in the US and Europe and potentially Latin
America.
Had you enrolled any patients in the trial
before the curve was flattened?
It’s a good news, bad news story. The good
news is that when the hospitals opened for
enrolment, suddenly they had no patients
who were eligible. We really are committed
to doing the trial though. One feature
about the trial is that it’s got what’s called
an adaptive design, which means instead
of being rigid and fixed in terms of what
we are going to study, if we see data that
comes from an overseas trial, we are quite
prepared to change the options.
It might be that the HIV drug or the
malaria drug don’t end up being used,
but something new from the US or from
Europe is slotted into the trial depending
on data that’s come through when we’re
ready to start the study.
This is the key study being done in
Australia and New Zealand. At the same
time, there is a huge amount of work being
done on vaccine development.
You’ve got to really, first of all, develop
a vaccine that has a chance of working. In
other words, ensuring it is something that
stimulates the immune system to prevent
an infection.
Then you’ve got to work out, is it safe?
Historically there have been vaccines that
have not had a great safety profile. Thirdly,
you’ve got to work out if this vaccine
produces lifelong immunity, and what is
the schedule you need to give? There are
some vaccines where you have the vaccine
and then you might have a booster six
months later. There’s a lot of work to be
discovered as to what is the right regimen.
Then how do you ramp up production
so that billions of people around the world
can get the vaccine? So there is an awful
lot, that normally takes 10 to 15 years,
realistically, that has to be compressed
into a very short period of time. That’s our
challenge. I don’t think we can truly imagine
that there’ll be a vaccine out in 2020.
By the time you ramp up production,
who decides who gets it, is it only to be
given to the elderly in nursing homes? Is
it only to be given to healthcare workers?
When do we have the capacity to really say
that we have a safe world where we’ve got
protection against this novel coronavirus?
In your experience, how often do we find
solutions for a sickness using existing
drugs?
One of the most famous or infamous
examples was Thalidomide, a drug used
in the 1960s to prevent morning sickness
in women. Notoriously, it was found to
have very, very serious birth defects in the
children of the mothers who took it.
But then interestingly, that drug was also
found to be effective in treating myeloma,
a type of blood cancer, obviously with very
strict conditions. That is one example of
where the drug was successfully used in a
completely different disease process.
One interesting opportunity is that
antimalarials and anti-HIV drugs are both
given by mouth, and both do have a history
of being used for long periods of time
in certain people. And so, that raises the
potential that you could even give one of
these medications as a preventative, but
that would again require large trials.
We’ve got to be sure that the safety
of those medications is sufficient that if
you were giving it to large numbers of
people who were actually healthy, trying
to prevent infection, that you could give it
safely with benefits, but without significant
risks.
We don’t have answers yet. We’ve got
trials underway, but let’s wait eagerly to see
the results so that we really do know how
we’re going to move forward.
You’re working on something where the
whole world is absolutely hanging out
and waiting for you guys to solve it. How
is that kind of pressure? Is it strange?
It’s strange, but it’s something that has
happened before. When I was a medical
student and then when I was a junior
doctor, every one of my patients with HIV
died. We had a situation there where, with
a lot of stimulus funding, we were able to
move ahead.
I’ve just come from my HIV clinic and
my patients are taking one pill once a day
and leading completely normal lives. That’s
what the infectious diseases profession has
been able to do in the past. We’re eager to
solve this problem of the novel coronavirus
so we can do it again. ■
nursingreview.com.au | 23